ARCHIVES

B-14 Trial: No Advantage To 10 Years Of Tamoxifen

This article is from The Cancer Letter archive.

Vol. 24 No. 5 | May 25, 2001

Download PDF Visit The Full Archive

Related Articles

Conversation With The Cancer Letter: How ASCO’s Guideline Differs—And Why

July 20, 2012

Congress Cuts $210 Million From NIH Budget For The Remainder of 2011

April 15, 2011

FDA Approves Abraxane And Alimta for NSCLC

October 26, 2012

Ambitious Radiation Oncology Research Plan Calls For “Concentrated Efforts” In Emerging Areas

June 12, 1987

ODAC Advice: Avoid ESAs In Curative Settings, Require Patients To Sign Informed Consent.

March 14, 2008

Guideline Revisions or Outstanding Investigator Grant Still Controversial

December 9, 1983